In addition to using expanded PBNK, CD19-CAR-NK cells (specific for the treatment of B-acute lymphoblastic leukemia) (20) were also included to show the specificity of S309-CAR-NKprimary against target cells expressing wild-type S protein or the D614G variant. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.